降脂药物与癌症风险

Lipid-lowering medication and risk of cancer.

作者信息

Olsen J H, Johansen C, Sørensen H T, McLaughlin J K, Mellemkjaer L, Steffensen F H, Fraumeni J F

机构信息

Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen.

出版信息

J Clin Epidemiol. 1999 Feb;52(2):167-9. doi: 10.1016/s0895-4356(98)00147-4.

DOI:10.1016/s0895-4356(98)00147-4

PMID:10201659

Abstract

Low or declining levels of serum cholesterol have been associated with increased mortality from cancer. We conducted a population-based cohort study of 1882 patients from one Danish county who received lipid-lowering drugs between January 1, 1991 and December 31, 1994. During the follow-up period of up to 4 years, 41 cancers were observed among users of lipid-lowering drugs, with 42.9 expected, to yield an age- and sex-standardized incidence ratio of 1.0 (95% confidence interval, 0.7-1.3). Although limited by small numbers and short follow-up period, examination by site of cancer and type of drug provided no evidence of an association. Further research is needed, however, with longer follow-up to assess more fully any potential cancer risk with these medications.

摘要

血清胆固醇水平低或呈下降趋势与癌症死亡率增加有关。我们对丹麦一个县的1882名患者进行了一项基于人群的队列研究，这些患者在1991年1月1日至1994年12月31日期间接受了降脂药物治疗。在长达4年的随访期内，降脂药物使用者中观察到41例癌症，预期为42.9例，年龄和性别标准化发病率比为1.0（95%置信区间，0.7-1.3）。尽管受样本量小和随访期短的限制，但按癌症部位和药物类型进行的检查未发现关联证据。然而，需要进一步开展研究，进行更长时间的随访，以更全面地评估这些药物的任何潜在癌症风险。